Study summary · research use only
The effect of treatment with the oral growth hormone (GH) secretagogue MK-677 on GH isoforms
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This human study examined 12 obese males who received 25mg of the oral growth hormone secretagogue MK-677 daily for an 8-week period, measuring the proportion of non-22K growth hormone isoforms and 20K growth hormone. The authors reported that the proportion of non-22K GH isoforms in peak samples was higher after the initial dose than after 2 and 8 weeks, while in non-peak samples it was similar across timepoints. The proportion of 20K GH in 2-h samples was lower after the initial dose than after 2 and 8 weeks. The authors described these as moderate changes of small importance to the clinical response to MK-677 treatment.
Abstract
Growth hormone (GH) consists of several isoforms. We have studied the proportion, expressed as percentage of total GH concentration, of non-22kDa (non-22K) GH isoforms and 20K GH during 8-week oral treatment with MK-677 25mg daily in 12 obese males. The proportion of non-22K GH isoforms in peak total GH samples after the initial MK-677 administration was higher than that after 2 and 8 weeks (p<0.01 and p<0.05, respectively). In selected non-peak total GH samples after the initial MK-677 administration, however, the proportion of non-22K GH isoforms was similar to that in the peak total GH samples after 2 and 8 weeks. The proportion of 20K GH in 2-h samples after the initial MK-677 administration was lower than that after 2 and 8 weeks (p<0.01 and p<0.05, respectively). We concluded that the proportion of non-22K GH isoforms was higher in peak, but not in non-peak, total GH samples after the initial MK-677 administration than that observed after multiple doses. The proportion of 20K GH in 2-h samples after the initial MK-677 administration was lower than that after 2 and 8 weeks. These moderate changes in the proportion non-22K GH isoforms are likely of small importance for the clinical response to MK-677 treatment.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.